KUALA LUMPUR (June 7): Genomics and biopharmaceutical company Malaysian Genomics Resource Centre Bhd (KL:MGRC) has entered into a strategic collaboration agreement (SCA) with South Korea-based Dx&Vx Co Ltd to collaborate in providing genome services.

In a bourse filing, MGRC said the SCA was inked between its wholly owned unit MGRC Therapeutics Sdn Bhd and Dx&Vx on Friday.

DxVx, which is listed on the Korean Securities Dealers Automated Quotations (Kosdaq), is involved in healthcare solutions, providing genomic testing services, companion diagnostics services and digital healthcare, as well as developing innovative new drugs and manufacturing food supplements for commercial sales worldwide.

Under the SCA, MGRC Therapeutics and Dx&Vx intend to introduce a genome service that analyses an individual’s genome information from prenatal to postnatal stages and throughout adulthood to the Malaysian market.

“The parties are of the view that there are synergistic benefits to be derived for the SCA through sharing and developing the knowledge and expertise of both parties in relation to the product, which is subject to the terms and conditions of the SCA,” MGRC said.

This marks the third collaboration agreement MGRC has entered since the beginning of this year. Last month, MGRC partnered an artificial intelligence service provider, Twistcode Technologies Sdn Bhd, to design a services platform for Malaysia and the Middle East. In March, the company collaborated with Universiti Sains Malaysia (USM) for research on genetics.

At Friday's noon market close, shares in MGRC were half a sen or 1.22% lower at 40.5 sen, giving the company a market capitalisation of RM55.57 million.